Baiyunshan(00874): Baiyunshan Pharmaceutical Factory has received the Macau Registration Certificate for Carboxymethylcystine Oral Solution 0.5g/10mL

Baiyunshan (00874) issued an announcement. Recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”) received the “Patent Medicines Registration Certificate” issued by the Macao Special Administrative Region’s Government Drug Regulatory Authority.

On March 5, 2026, Baiyunshan Pharmaceutical’s general plant submitted to the Macao Special Administrative Region’s Government Drug Regulatory Authority a drug registration application for “Carbocisteine Oral Solution 0.5 g/10 mL” and the application was accepted.

Carbocisteine Oral Solution is an over-the-counter expectorant. Its main ingredient is carbocisteine. Its indications are to reduce the viscosity of phlegm and promote the expulsion of phlegm. It is used for patients with phlegm characterized by viscous sputum and difficulty in expectoration caused by diseases such as chronic bronchitis and bronchial asthma.

According to data from the Minee Network, in 2025, the sales revenue of Carbocisteine Oral Solution in domestic cities, county-level public hospitals, and urban and online pharmacies was RMB 701 million. In 2025, the sales revenue of Baiyunshan Pharmaceutical’s general plant’s Carbocisteine Oral Solution was RMB 22.74 million.

As of the date of this announcement, Baiyunshan Pharmaceutical’s general plant has already invested total research and development expenses of approximately RMB 1.43 million (unaudited) on this drug R&D project.

After obtaining the “Patent Medicines Registration Certificate” issued by the Macao Special Administrative Region’s Government Drug Regulatory Authority, the drug will be sold in the Macao region under authorization from Baiyunshan Pharmaceutical’s general plant to Desantang Pharmaceutical Products Import & Export and Wholesale Company, which will help Baiyunshan Pharmaceutical’s general plant expand its overseas market business and enhance the market competitiveness of the Company’s products. The obtaining of the “Patent Medicines Registration Certificate” will have no material impact on the Company’s performance for the current period.

A wealth of information and precise analysis—on the Sina Finance app